Use of supportive care and risk of febrile neutropenia (FN) among patients receiving myelosuppressive chemotherapy for solid tumors or non-Hodgkin's lymphoma (NHL) at four US health systems.

Derek Weycker,Amanda Silvia,Erinda Shyta,Kathryn Richert-Boe,Mark Bensink,Lois Lamerato,Manpreet Kaur,James J. Rooney,David Chandler

Use of supportive care and risk of febrile neutropenia (FN) among patients receiving myelosuppressive chemotherapy for solid tumors or non-Hodgkin's lymphoma (NHL) at four US health systems.

2018

Derek Weycker
Amanda Silvia
Erinda Shyta
Kathryn Richert-Boe
Mark Bensink
Lois Lamerato
Manpreet Kaur
James J. Rooney
David Chandler

e18756Background: Although clinical practice guidelines recommend use of colony-stimulating factors (CSFs) for prevention of FN among many patients receiving myelosuppressive chemotherapy, detailed...

Keywords:

Myelosuppressive Chemotherapy
Non-Hodgkin's lymphoma
Febrile neutropenia
Pathology
Oncology
Medicine
Internal medicine
Clinical Practice
healthcare system
Physical therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations